A new Medicare pilot program offering GLP-1 medications for weight loss at a reduced cost of $50 per month has encountered issues with patient eligibility. While intended to help those struggling with the high price of drugs like Zepbound, the program excludes individuals with certain qualifying medical conditions, such as severe obstructive sleep apnea or Type 2 diabetes, even if weight loss is a primary concern. These patients are instead routed back to standard Medicare Part D plans, which often result in significantly higher out-of-pocket expenses. AI
RANK_REASON This is a news item about a specific program's implementation details and patient impact, not a new product release or major policy shift.
- Bridge program
- Centers for Medicare & Medicaid Services
- Foundayo
- GLP-1
- Jeff La Marca
- Juliette Cubanski
- Medicare
- United States Food and Drug Administration
- Wegovy
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
